Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

oritavancin 400 MG Injection

Known as: ORITAVANCIN 400MG/VIL INJ, ORITAVANCIN 400MG/VIL INJ [VA Product], oritavancin (as oritavancin diphosphate) 400 MG Injection 
 
National Institutes of Health

Related topics

Related topics

5 relations
Anti-Bacterial AgentsBacterial InfectionsInjectionLipoglycopeptides [Chemical/Ingredient]
Expand

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Inhibition of d-Ala incorporation into wall teichoic acid in Staphylococcus aureus by desleucyl-oritavancin.
The mode of action for desleucyl-oritavancin was investigated by adding an antibiotic to Staphylococcus aureus during its growth… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2017
2017
In vitro activity of Oritavancin against gram-positive pathogens isolated in Canadian hospital laboratories from 2011 to 2015.
Gram-positive bacterial pathogens isolated from patient specimens submitted to 15 Canadian hospital laboratories from 2011 to… Expand
Is this relevant?
2014
2014
In vitro activity of oritavancin against Gram-positive pathogens isolated in Canadian hospital laboratories from 2011 to 2013.
Gram-positive pathogens isolated in 15 Canadian hospital laboratories between 2011 and 2013 were tested for susceptibility to… Expand
  • table 1
  • table 1
  • figure 1
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Comparative In Vitro Activity Profile of Oritavancin against Recent Gram-Positive Clinical Isolates
ABSTRACT Oritavancin activity was tested against 15,764 gram-positive isolates collected from 246 hospital centers in 25… Expand
  • table 1
  • table 2
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE